Literature DB >> 17057332

Crystal structures of two peptide-HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype.

Gustav Røder1, Thomas Blicher, Sune Justesen, Birthe Johannesen, Ole Kristensen, Jette Kastrup, Søren Buus, Michael Gajhede.   

Abstract

MHC class I molecules govern human cytotoxic T cell responses. Their specificity determines which peptides they sample from the intracellular protein environment and then present to human cytotoxic T cells. More than 1100 different MHC class I proteins have been found in human populations and it would be a major undertaking to address each of these specificities individually. Based upon their peptide binding specificity, they are currently subdivided into 12 supertypes. Several of these HLA supertypes have not yet been described at the structural level. To support a comprehensive understanding of human immune responses, the structure of at least one member of each supertype should be determined. Here, the structures of two immunogenic peptide-HLA-B*1501 complexes are described. The structure of HLA-B*1501 in complex with a peptide (LEKARGSTY, corresponding to positions 274-282 in the Epstein-Barr virus nuclear antigen-3A) was determined to 2.3 A resolution. The structure of HLA-B*1501 in complex with a peptide (ILGPPGSVY) derived from human ubiquitin-conjugating enzyme-E2 corresponding to positions 91-99 was solved to 1.8 A resolution. Mutual comparisons of these two structures with structures from other HLA supertypes define and explain the specificity of the P2 and P9 peptide anchor preferences in the B62 HLA supertype. The P2 peptide residue binds to the B-pocket in HLA-B*1501. This pocket is relatively large because of the small Ser67 residue located at the bottom. The peptide proximal part of the B-pocket is hydrophobic, which is consistent with P2 anchor residue preference for Leu. The specificity of the B-pocket is determined by the Met45, Ile66 and Ser67 residues. The apex of the B-pocket is hydrophilic because of the Ser67 residue. The P9 peptide residue binds to the F-pocket in HLA-B*1501. The residues most important for the specificity of this pocket are Tyr74, Leu81, Leu95, Tyr123 and Trp147. These residues create a hydrophobic interior in the F-pocket and their spatial arrangement makes the pocket capable of containing large, bulky peptide side chains. Ser116 is located at the bottom of the F-pocket and makes the bottom of this pocket hydrophilic. Ser116, may act as a hydrogen-bonding partner and as such is a perfect place for binding of a Tyr9 peptide residue. Thus, based on structure information it is now possible to explain the peptide sequence specificity of HLA-B*1501 as previously determined by peptide binding and pool sequencing experiments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17057332     DOI: 10.1107/S0907444906027636

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  14 in total

1.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

3.  Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition.

Authors:  Alex Theodossis; Carole Guillonneau; Andrew Welland; Lauren K Ely; Craig S Clements; Nicholas A Williamson; Andrew I Webb; Jacqueline A Wilce; Roger J Mulder; Michelle A Dunstone; Peter C Doherty; James McCluskey; Anthony W Purcell; Stephen J Turner; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

4.  HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.

Authors:  Y Yang; S Chen; F Yang; L Zhang; G Alterovitz; H Zhu; J Xuan; X Yang; H Luo; J Mu; L He; X Luo; Q Xing
Journal:  Pharmacogenomics J       Date:  2016-08-16       Impact factor: 3.550

5.  A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.

Authors:  F David Carmona; Sarah L Mackie; Jose-Ezequiel Martín; John C Taylor; Augusto Vaglio; Stephen Eyre; Lara Bossini-Castillo; Santos Castañeda; Maria C Cid; José Hernández-Rodríguez; Sergio Prieto-González; Roser Solans; Marc Ramentol-Sintas; M Francisca González-Escribano; Lourdes Ortiz-Fernández; Inmaculada C Morado; Javier Narváez; José A Miranda-Filloy; Lorenzo Beretta; Claudio Lunardi; Marco A Cimmino; Davide Gianfreda; Daniele Santilli; Giuseppe A Ramirez; Alessandra Soriano; Francesco Muratore; Giulia Pazzola; Olga Addimanda; Cisca Wijmenga; Torsten Witte; Jan H Schirmer; Frank Moosig; Verena Schönau; Andre Franke; Øyvind Palm; Øyvind Molberg; Andreas P Diamantopoulos; Simon Carette; David Cuthbertson; Lindsy J Forbess; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry Moreland; Paul A Monach; Christian Pagnoux; Philip Seo; Robert Spiera; Antoine G Sreih; Kenneth J Warrington; Steven R Ytterberg; Peter K Gregersen; Colin T Pease; Andrew Gough; Michael Green; Lesley Hordon; Stephen Jarrett; Richard Watts; Sarah Levy; Yusuf Patel; Sanjeet Kamath; Bhaskar Dasgupta; Jane Worthington; Bobby P C Koeleman; Paul I W de Bakker; Jennifer H Barrett; Carlo Salvarani; Peter A Merkel; Miguel A González-Gay; Ann W Morgan; Javier Martín
Journal:  Am J Hum Genet       Date:  2015-03-26       Impact factor: 11.025

6.  MFPred: Rapid and accurate prediction of protein-peptide recognition multispecificity using self-consistent mean field theory.

Authors:  Aliza B Rubenstein; Manasi A Pethe; Sagar D Khare
Journal:  PLoS Comput Biol       Date:  2017-06-26       Impact factor: 4.475

7.  Identification of putative unique immunogenic ZIKV and DENV1-4 peptides for diagnostic cellular based tests.

Authors:  Aaron L Oom; Davey Smith; Kevan Akrami
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

8.  Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

Authors:  Rebecca Pavlos; Elizabeth J McKinnon; David A Ostrov; Bjoern Peters; Soren Buus; David Koelle; Abha Chopra; Ryan Schutte; Craig Rive; Alec Redwood; Susana Restrepo; Austin Bracey; Thomas Kaever; Paisley Myers; Ellen Speers; Stacy A Malaker; Jeffrey Shabanowitz; Yuan Jing; Silvana Gaudieri; Donald F Hunt; Mary Carrington; David W Haas; Simon Mallal; Elizabeth J Phillips
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

9.  A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.

Authors:  Jugmohit S Toor; Arjun A Rao; Andrew C McShan; Mark Yarmarkovich; Santrupti Nerli; Karissa Yamaguchi; Ada A Madejska; Son Nguyen; Sarvind Tripathi; John M Maris; Sofie R Salama; David Haussler; Nikolaos G Sgourakis
Journal:  Front Immunol       Date:  2018-01-30       Impact factor: 7.561

10.  Structure of a SARS coronavirus-derived peptide bound to the human major histocompatibility complex class I molecule HLA-B*1501.

Authors:  Gustav Røder; Ole Kristensen; Jette S Kastrup; Søren Buus; Michael Gajhede
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.